Safety Analysis of Oxymetazoline Eye Drops for Blepharoptosis Using the FDA Adverse Event Reporting System

Key Points

• The analysis aims to assess the safety of oxymetazoline eye drops in treating blepharoptosis by examining adverse events.
• Analyzed data from the FDA Adverse Event Reporting System
• Identified and corroborated existing adverse drug events (ADEs)
• Investigated new safety signals related to ocular treatments
• Confirmed ADEs such as ocular surface disease and conjunctival hyperemia
• Identified new signals including vitreoretinal complications and hypertension
• Noted transient blurred vision, instillation site pain, and headache as common side effects

Abstract